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Background: Previous predictionmodels for recurrent thromboembolism (VTE) are often
complicated to apply and have not been implemented widely.
Aim: To develop and internally validate a potential new predictionmodel for recurrent VTE
that can be used without stopping anticoagulant treatment for D-dimer measurements
in patients with provoked and unprovoked DVT.
Methods: Cohort data of 479 patients treated in a clinical care pathway at Maastricht
University Medical Center were used. Predictors for the Cox proportional hazards
model (unprovoked DVT, male gender, factor VIII levels) were derived from literature
and using forward selection procedure. The scoring rule was internally validated
using bootstrapping techniques and the predictive ability was compared to existing
prediction models.
Results: Patients were followed for a median of 3.12 years after stopping
anticoagulation treatment (IQR 0.78, 3.90). Sixty-four of 479 patients developed recurrent
VTE (13%). The scoring rule consisted of unprovoked DVT (yes: 2 points), male sex (yes:
1 point), and factor VIII > 213 % (yes: 2 points) and was categorized into three groups
[i.e., low risk (score 0), medium risk (scores 1, 2, or 3) and high risk (scores 4 and 5)].
The concordance statistic was 0.68 (95% CI: 0.61, 0.75).
Conclusion: The discriminative ability of the new Continu-8 score was adequate.
Future studies shall verify this score in an independent setting without stopping
anticoagulation treatment.
Keywords: venous thrombosis/epidemiology, venous thrombosis/therapy, venous thrombosis/mortality, risk
factors, clinical decision making, health services research
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INTRODUCTION
Secondary prevention of venous thromboembolism (VTE) is
important to improve care in patients with deep vein thrombosis
(DVT) or pulmonary embolism (PE) (1–4). VTE is the thirdmost
common cardiovascular disease, and it contributes relevantly to
the global disease burden (1–3, 5, 6). The estimated incidence is
between 1 and 2 per 1,000 person-years and it is associated with
a significant morbidity and mortality, both in short-term and
long-term perspectives (5, 7, 8). In addition, VTE is associated
with substantial healthcare costs (9–11). Though anticoagulation
treatment is very effective in treatment and prevention of VTE,
it is associated with a significant risk of bleeding complications
(12–14); the corresponding case-fatality rate is estimated to be
6% (7). To guide treatment decisions in secondary prevention
of VTE, it is important to discriminate those 25% of patients
who will recur within 5 years from the 75% of patients who will
not (2).
A number of predictors for VTE recurrence have been
identified, the presence of reversible risk factors and active cancer
being the most relevant (14–16). Consistently, all large cohort
studies found an association between the absence of reversible
risk factors such as recent surgery, pregnancy and estrogen
treatment, and recurrent VTE (2, 14, 17). Men bear a 2-fold
risk of VTE recurrence compared to women (18). In addition,
elevated D-dimers 1 months after stopping anticoagulation are
associated with a high risk of VTE recurrence (19–21). The
drawback of a management according to D-dimer levels is that
anticoagulation must be stopped at least for 1 month. Factor VIII
was studied as another surrogate for an increased coagulation
activity by several authors (22–24). More predictors have been
suggested in patients without cancer, the applicability in clinical
practice is however limited (2). How to combine the predictors
optimally is still elusive.
Several prediction models for recurrence of VTE have been
developed, yet none of them is strongly recommended so
far (14, 25, 26). Rodger and colleagues followed 600 patients
with a first, unprovoked proximal VTE for a median of 18
months after stopping anticoagulant treatment and studied 69
predictors using a logistic regression model in males and females
(“HERDOO2”) (27, 28). D-dimer, age, body mass index, and
post-thrombotic signs were included in the model. However,
the risk of overfitting was high (2.5 events per predictor) and
the application is limited to women with an unprovoked VTE
(25). The prediction rule was validated in a prospective cohort
management study (28). Eichinger and colleagues included
929 patients with a first, unprovoked proximal or distal VTE,
and followed the patients for a median of 43.3 months after
stopping anticoagulation treatment (29). Eight prespecified
predictors were studied in 176 recurrent events (22 events per
predictor) in a Cox proportional hazards model (the “Vienna
predictionmodel”). Finally, quantitative D-dimermeasurements,
sex and site of index event were included in the model.
The Vienna prediction model was updated (30) and externally
validated in two other cohorts with varying results (31, 32).
The “DASH” score was derived using individual patient-data
from seven prospective studies including patients with a first
episode of proximal VTE (33). Six variables obtained from
univariate analysis and theoretical considerations were included
in a Cox regression analysis and the model was derived
from backward selection (40 events per predictor). The final
model comprised D-dimer, age, sex, and hormone therapy.
The DASH score was externally validated in a retrospective
cohort (34).
Several important limitations appear with regard to the
existing prediction rules: (1) anticoagulation treatment shall be
stopped for measuring D-dimers, (2) the application is difficult,
and (3) the application is limited to patients with unprovoked
VTE in case of the DASH and HERDOO2 score (25).
With the present investigation, we aimed to develop and
internally validate a potential new prediction model for recurrent
VTE that can be used in patients with provoked and unprovoked
proximal DVT without stopping anticoagulant treatment.
METHODS
Study Design, Setting and Population
Data of a prospective cohort study observing patients with
a proximal DVT were used, the details of which have been
published (15). All consecutive patients treated within a clinical
care pathway (CCP) at Maastricht University Medical Center
(MUMC) were included. Inclusion criteria were (a) objectively
confirmed first proximal lower extremity DVT (popliteal vein,
femoral vein, common femoral vein, iliac vein), (b) diagnosed
at MUMC between 1st of June 2003 and 30th of June 2013,
and (c) aged 18 or older. Patients were managed in a specialized
outpatient unit for 2 years as part of the CCP (Figure 1). Details
of the CCP including risk assessment and treatment decisions
are described elsewhere (15). Some patient groups were usually
not treated within the CCP: distal DVT, pulmonary embolism,
and patients with cancer. MUMC is the only tertiary hospital in
the province of Limburg, the Netherlands. The study protocol
was approved by the appropriate ethical committee (METC 15-
4-256) and it was carried out in accordance with the Declaration
of Helsinki.
Collection of Data and Determination of
Laboratory Tests
All data were collected prospectively in-line with clinical routine
and were recorded in a structured database. Regular visits were
scheduled until 24months. At the first visit of the CCP, structured
history was taken as well as physical examination. Clinical risk
factors were assessed. Laboratory tests were performed 1 months
after stop anticoagulant treatment (e.g., D-dimer, factor VIII).
Clinical outcomes were assessed until the last visit. Patients were
additionally followed over the course of further outpatient visits
and accessingMUMC and general practitioner records. Observer
were not aware about outcomes while assessing predictors and
predictors while assessing outcomes, respectively. Laboratory
tests were conducted at pre-specified time points as previously
described (35). A protocol was implemented to ensure adequate
pre-analytical conditions (15). D-dimer levels were determined
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FIGURE 1 | Flow of the patients. MUMC, Maastricht University Medical Center.
using the Vidas assay (bioMérieux Clinical Diagnostics, Marcy-
l’Etoile, France) or Innovance, respectively (Siemens Healthcare,
Marburg, Germany). Factor VIII was analyzed using a one-
stage assay (Actin FS, Siemens Healthcare, Marburg, Germany)
on a Sysmex CA7000 (distributed by Siemens Healthcare,
Marburg, Germany).
Definition of Outcomes and Predictor
Variables
We defined recurrent VTE as symptomatic, objectively
confirmed proximal or distal DVT, PE, or other venous
thrombosis, whereas confirmation was done using compression
ultrasound, spiral computed tomography, or ventilation-
perfusion lung scanning. A diagnostic work-up was conducted
in case of signs and symptoms suggesting VTE as done in
routine clinical practice. Recurrence of DVT was defined as
(a) a new non-compressible vein in the contralateral leg, (b) a
new non-compressible vein of the same leg as the first event
(previously unaffected), (c) a clear proximal extension of the
known thrombus, or (d) a new non-compressible site of a
vein that was effected but previously re-canalized (15, 36–38).
D-dimer were defined as positive if above or equal 500 ng/ml.
Factor VIII was considered positive if above or equal 213% (80th
percentile of the study population). “Unprovoked DVT” was
defined as DVT without the presence of a reversible risk factor
(20). All other variables investigated in the cohort study were
defined previously (20).
Selection of Predictors for Model
Development
The selection of predictor variables was based on five principles:
(a) firmly established risk factors for recurrence, (b) easy to
determine in clinical practice, (c) must be applicable in a broad
range of patients. (d) the predictive value must be high in our
own cohort, (e) maximum four predictors to avoid overfitting.
The following risk factors were considered because of previous
publications: (1) Unprovoked DVT of the index event is
considered to be the most important risk factor for recurrence.
This was confirmed in many cohort studies in different settings
and populations (14). In contrast to previous prediction models,
we included this factor in the prediction model making it
applicable to patients with provoked DVT as well. (2) Male
sex is an established risk factor for VTE recurrence. A higher
risk of recurrence in men was observed in a number of cohort
studies and an individual-patient meta-analysis summarizing this
evidence estimated a 2.2-fold higher risk in men compared to
women (18). This variable was already implemented in two
previous prediction models (Vienna prediction model; DASH
score). (3) Elevated D-dimer measured 1 month after stopping
anticoagulation is associated with an increased risk of recurrent
VTE. A systematic review and meta-analysis summarizing the
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data estimated an 8.9% annual risk in patients with elevated D-
dimer compared to 3.5% annual risk in patients without (19). We
decided however not to include D-dimer in the prediction model
in order to avoid the requirement of stopping the anticoagulation
for 1 month. (4) Different cohort studies observed a higher
risk of recurrence in patients with a high factor VIII compared
to patients without (23, 24, 39). Presence of inflammation was
defined as an active systematic inflammatory disorder such
as inflammatory bowel disease or inflammatory rheumatologic
disease (39).
Model Building and Statistical Analysis
Numbers/ frequencies or median/ inter-quartile ranges was
reported to describe patient characteristics. The subgroups
“provoked by surgery,” “non-surgical transient risk factor,”
“unprovoked VTE,” as well as “active cancer” are mutually
exclusive groups. Incidence rates per 100 patient-years
were reported.
A commonly used rule-of-thumb states that at least 10 events
should be recorded for each predictor included in the analysis.
We allowed amaximum of 4 predictors, corresponding to over 15
events per predictor variable. Incomplete predictor values were
imputed using stochastic regression imputation to prevent a loss
of statistical precision and to reduce the likelihood of selection
bias. A cox proportional hazards model was used to determine
associations between predictor variables and recurrent VTE. The
analysis was adjusted for periods of anticoagulation by including
this variable as a time-varying co-variable. We used stepwise
forward selection to arrive at a model containing only predictors
that contributed significantly to the model, using a relatively
liberal p-value for selection of 0.10 to make sure potentially
important predictors would not be omitted. Using the regression
coefficients (i.e., the natural logarithm of the hazard ratios) we
simplified the model into a score based on integers only by
selecting the smallest whole numbers that would still preserve the
relative differences in importance between predictors. To adjust
for potential overfitting, standard bootstrapping techniques were
used to internally validate the model. Using the 1,000 bootstrap
samples, we corrected the optimism-corrected C-statistic, which
is an estimation of the C-statistic when the model is applied
to future patients. The C-statistic, or concordance statistic, is
a measure of discrimination (i.e., the ability of the model to
separate outcomes). Patients were ranked according to their risk
score and we created three groups of roughly similar size. As
long as a risk score that has no unit rather than a prediction
model was build, we did not create calibration plots and did
not calculate the agreement between predicted and observed
outcomes. A Kaplan-Meier curve stratified by risk category was
used instead to assess differences in time-to-event between risk
groups. A sensitivity analysis was conducted after excluding
cancer patients.
The R statistical package was used for analysis [R
Development Core Team (2019). R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0,
URL http://www.R-project.org.].
RESULTS
Patient Characteristics and VTE
Recurrence
Four-hundred and seventy-nine patients were included in the
study cohort and followed for a median of 3.12 years (IQR
0.78, 3.90) after stopping anticoagulation treatment. Patient
characteristics are reported in Table 1. Five patients were lost
to follow-up within the 2 years of CCP (1%; moved abroad),
and 17 patients were lost during the extended follow-up (3.6%;
Figure 1). Median age was 58.0 years (inter-quartile range, IQR
46.1, 71.1), and 242 were female (50.5%). All patients received
vitamin K antagonists. Unprovoked DVT was present in 265
cases (55.3%). Sixty-four recurrent VTE were observed (25%
of the patients), comprising 39 patients with DVT (60.9%), 20
patients with PE (31.3%), and 5 patients with other VTE (7.8%).
Predictors of Recurrent VTE
The full list of predictors analyzed are reported in a previous
publication (15). Five predictors were statistically significant
TABLE 1 | Patient characteristics (n = 479)*.
Characteristics Frequency Missing values
Number (%) Numbers
Age (median, IQR) 58.0 (46.1, 71.1) 0
Females 242 (50.5) 0
Risk factors
Provoked by surgery◦ 95 (19.9) 0
Non-surgical transient risk factor◦ 107 (22.3) 0
Unprovoked VTE◦ 265 (55.3) 0
Active cancer◦ 12 (2.5) 0
Pregnancy 6 (1.3) 0
Contraceptive use 50 (10.4) 6
Travel 34 (7.1) 0
Immobilization 40 (8.4) 6
Inflammation 64 (13.4) 7
Previous VTE 91 (19.0) 0
Cardiovascular disease 115 (24.0) 5
Heart failure 6 (1.3) 6
Known thrombophilia 19 (4.0) 7
Venous insufficiency 31 (6.5) 8
Varicosis 22 (4.6) 177
Residual thrombosis† 144 (30.1) 60
Smoking 107 (22.3) 29
Family history 140 (29.2) 14
Elevated D-dimer& 112 (23.4) 122
Elevated CRP& 109 (22.8) 174
Elevated FVIII& 65 (13.6) 157
Elevated Villalta score$ 78 (16.3) 96
*Observation period 2,231 patient-years; median 3.1 years; five patients were lost
to follow-up because they moved abroad; ◦mutually exclusive groups;
†
determined
1 week before intended stop of anticoagulation treatment; &1 month after stopping
anticoagulation treatment; $at 6 months.
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in univariate analysis: (1) unprovoked VTE, (2) male sex, (3)
elevated D-dimer, (4) high factor VIII, and (5) presence of
inflammation. The corresponding number of events, incidence
rates per 100 patient-years, and unadjusted hazard ratios are
reported in Table 2.
Development and Performance of the
Prediction Model
Using the predictors mentioned above, we added “unprovoked
VTE,” “male sex,” “high factor VIII,” and “presence of
inflammation” in a stepwise manner to the multivariable
Cox proportional hazards model. We skipped D-dimer for
practicability reasons (discussed above). The variable “presence
of inflammation” and was omitted from the final model beause it
did not improve the discrimitative ability. The adjusted hazard
ratios (HR’s) for unprovoked VTE, male sex, and high factor
VIII were 2.19 [95% confidence interval (CI): 1.22–3.91, p =
0.008], 1.62 (95% CI: 0.95–2.77, p = 0.077), and 2.07 (95%
CI: 1.23–3.47, p = 0.006), respectively. A sensitivity analysis
after excluding cancer patients (n = 12) did not change these
HR. After converting to integers, the score ranged from 0 to
5 and was categorized into three groups [i.e., low risk (score
0), medium risk (scores 1, 2, or 3) and high risk (scores 4 and
5)]. The 5-years probability of recurrence for the low, medium,
and high-risk groups was 7.7% (95% CI: 2.9–12.2%), 12.1%
(95% CI: 4.2–19.3%), and 29.1% (95% CI: 20.9–36.5%). Figure 2
illustrates the cumulative recurrence according to risk categories
of the Continu-8 score. The optimism-corrected C-statistic of the
Continu-8 score was 0.68 (95% CI 0.61, 0.75).
DISCUSSION
Using data from a prospective cohort study following patients
with a proximal DVT, we developed and internally validated a
potential new prediction model for recurrent VTE that can be
used in patients with provoked and unprovoked proximal DVT
without stopping anticoagulant treatment. The performance of
the prediction model was adequate.
Our findings are essentially in-line with previous studies.
The four most important predictors were already confirmed
in other observational studies: (a) unprovoked DVT (2, 14,
17, 40, 41), (b) male sex (18), (c) elevated D-dimer (19), and
(d) high factor VIII (22–24, 42, 43). In addition, inflammatory
conditions were associated with recurrent VTE (44); this effect
was however not significant anymore in multivariate analysis. In
contrast to older studies, the risk of recurrence was very low in
patients with pregnancy-related DVT or contraceptive use (45).
In fact, the number of recurrent events is very low, leading to
wide confidence intervals, and impeding the implementation in
the prediction model. Our interpretation is that the awareness
on the pregnancy and estrogen-related risk is much higher
nowadays, leading to strict avoidance or medical prophylaxis in
such patients.
Previous prediction models were developed in patients
with unprovoked VTE only (25, 27, 29, 33). In contrast, we
incorporated this variable in order to apply the model to all
FIGURE 2 | Kaplan-Meier curves illustrating cumulative recurrence according
to risk categories of the Continu-8 score. The 5-years probability was 7.7% in
the low-risk group (95% CI: 2.9–12.2%), 12.1% in the medium-risk group
(95% CI: 4.2–19.3%), and 29.1% in the high-risk group (95% CI: 20.9–36.5%).
TABLE 2 | Recurrence rates and hazard ratios according to predictor variables.
Predictor variable Events
(numbers)




Points attributed in the
prediction model‡
All patients 64 2.9 (2.2, 3.7) N/A
Unprovoked DVT 47 4.0 (3.0, 5.3) 3.1 (1.3, 7.4) 2
Male sex 41 3.9 (2.9, 5.3) 2.0 (1.2, 3.3) 1
Elevated D-dimer+ 26 5.1 (3.4, 7.4) 2.5 (1.5, 4.3)
High factor VIII+ 17 5.2 (3.2, 8.3) 2.3 (1.3, 4.2) 2
Presence of inflammation 15 4.7 (2.9, 7.9) 1.9 (1.1, 3.4)
*Cox proportional hazards model adjusted for periods of anticoagulation by including this variable as a time-varying co-variable;+ assessed 1 month after stop anticoagulation treatment;
‡
patients will be categorized into three groups: low risk (score 0), medium risk (scores 1, 2, or 3) and high risk (scores 4 and 5).
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patients with proximal DVT, extending the prediction model to a
more broader range of patients. Male sex was already included
in the Vienna prediction model as well as the DASH score
(29, 33). In contrast to HERDOO2 (27), Vienna prediction model
(29, 30), and DASH (33), we did not include D-dimer in order
to facilitate risk assessment without stopping anticoagulation
treatment. High factor VIII was added to the DASH score in
a sub-analysis of the MEGA follow-up study investigating the
predictive value of factor VIII for recurrent VTE, what improved
the c-statistics of the DASH score (22). We did also not include
age (27, 33), body mass index (27), presence of post-thrombotic
syndrome (27), and site of index event (29) in the model.
The strength of our investigation is that a relatively high
number of events were available per predictor (64 events for 4
predictors studies), resulting in a considerable precision of the
estimates. In addition, it was conducted in a reasonable number
of patients, conducting a long-term follow-up, combined with
a low number of patients lost. Of course, we are faced with
limitations as well. First, only patients with (proximal) DVT were
studied. At the present moment, the results of our study cannot
be applied to patients with PE. We believe however that future
external validations will confirm our results because previous
prediction models using similar sets of predictors were generated
in populations including PE (22, 27, 29, 30, 33). Secondly, a very
low number of patients with cancer were included, preventing
the application of the prediction model to this special group
of patients. Thirdly, factor VIII was measured after stopping
anticoagulation. Even though the impact of anticoagulation
treatment on factor VIII measurements is assumed to be low,
we cannot fully exclude that the results would be different
while continuing anticoagulation treatment. Fourthly, due to
the specific characteristics of the study population (proximal
DVT as index event only, few cancer patients) and the predictor
variables implemented in the model (unprovoked DVT, sex,
increased coagulation activity), we were not able to conduct
sensitivity analyses in meaningful subgroups of patients to assess
the internal validity. However, our results are essentially in-
line with previous studies suggesting external validity. Fifthly,
the exact number of patients with distal DVT as the recurrent
event type was not recorded. However, there were few patients
only and we do not believe that this might have introduced
any bias. Sixthly, even though bootstrapping techniques were
used to adjust for potential overfitting, we cannot fully exclude
that such effects might have affected the results. Seventhly, we
did not discuss a risk-benefit trade-off to decide on the cut-
off to be considered for prolonged anticoagulation. Given the
apparent limitations of the study, this was beyond the focus of the
current manuscript. Eighthly, we did not include age-adjusted D-
Dimer cut-offs in the predictionmodel because it was beyond this
manuscript’s focus. Ninthly, our data were obtained with vitamin
K-antagonists used in most patients and we cannot fully exclude
that this might have affected the results.
What do the results of the study mean for scientific inquiry
and clinical practice? First, our study confirms that prediction
models or clinical prediction rules, respectively, can be applied
to patients with DVT. Even though a c-value of 0.68 is not a
high number, it is similar to previous prediction models (27,
29, 30, 33). Thus, the predictive ability of our score appears to
be adequate and supports further investigation. Besides, it was
possible to apply the prediction rule to all patients with proximal
DVT, not only unprovoked DVT. Secondly, the set of predictors
resembles previous prediction rules, verifying these results as
well (27, 29, 30, 33). Third, the set of predictors incorporated in
prediction models for recurrent VTE can be simplified to few
variables that can be easily scored in clinical practice. Fourth,
factor VIII measurements might replace D-dimer in order to
prevent stopping anticoagulation. However, these results must
be verified in patients with different settings and populations. In
particular, future studies might confirm these results in patients
without stopping anticoagulation while measuring factor VIII.
With the present investigation, we were able to develop
and validate a new prediction model to be used in patients
with both, provoked and unprovoked DVT, potentially
without stopping anticoagulation treatment. Awaiting external
validation in patients with PE and other populations and
settings without stopping anticoagulation treatment, the
prediction model has the potential to improve care in patients
with VTE.
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